Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

被引：11

作者：

Itzykson, R. ^{[1
]}

Thepot, S. ^{[1
]}

Beyne-Rauzy, O. ^{[2
]}

Ame, S. ^{[3
]}

Isnard, F. ^{[4
,5
]}

Dreyfus, F. ^{[6
,7
]}

Salanoubat, C. ^{[8
]}

Taksin, A. L. ^{[9
]}

Chelgoum, Y. ^{[10
]}

Berthon, C. ^{[11
]}

Malfuson, J. V. ^{[12
]}

Legros, L. ^{[13
]}

Vey, N. ^{[14
]}

Turlure, P. ^{[15
]}

Gardin, C. ^{[1
]}

Boehrer, S. ^{[1
]}

Ades, L. ^{[1
]}

Fenaux, P. ^{[1
]}

机构：

[1] Hop Avicenne, AP HP, Serv Hemat Clin, Paris, France

[2] Ctr Hosp Univ Toulouse, Serv Med Interne, Toulouse, France

[3] Ctr Hosp Univ Strasbourg, Serv Hematooncol, Strasbourg, France

[4] Hop St Antoine, AP HP, Serv Hematol, F-75571 Paris, France

[5] Univ Paris 06, Paris, France

[6] Hop Cochin, AP HP, Serv Hematol Clin, Paris, France

[7] Univ Paris 05, F-75270 Paris 06, France

[8] Ctr Hosp Sud Francilien, Serv Hematol, Corbeil Essonnes, France

[9] Hop Andre Mignot, Serv Hematooncol, Le Chesnay, France

[10] Hop Edouard Herriot, Serv Hematol, Lyon, France

[11] Ctr Hosp Univ CHU Lille, Serv Malad Sang, Lille, France

[12] Hop Instruct Armees Percy, Serv Hematol, Clamart, France

[13] Ctr Hosp Univ Nice, Serv Hematol, Nice, France

[14] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[15] Ctr Hosp Univ Limoges, Serv Hematol Clin, Limoges, France

来源：

LEUKEMIA RESEARCH | 2012年 / 36卷 / 04期

关键词：

Myelodysplastic syndromes; Hypomethylating agents; Erythropoiesis stimulating agents; INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; SURVIVAL; ANEMIA; CARE;

D O I：

10.1016/j.leukres.2011.11.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We studied a retrospective cohort of 282 higher-risk MDS treated with azacitidine, including 32 patients who concomitantly received an ESA for a median of 5.8 months after azacitidine onset. Forty-four percent of ESA and 29% of no-ESA patients reached HI-E (p = 0.07); 48% and 20% achieved transfusion independence (p = 0.01). Median OS was 19.6 months in the ESA and 11.9 months in the no-ESA groups (p = 0.04). Addition of an ESA significantly improved OS (p = 0.03) independently of azacitidine schedule and duration, and of our proposed azacitidine risk score (Blood 2011;117:403-11). Adding an ESA to azacitidine in higher-risk MDS should be studied prospectively. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：397 / 400

页数：4

共 13 条

[1] The non-haematopoietic biological effects of erythropoietin
Arcasoy, Murat O.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (01) : 14 - 31
[2] Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/- Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone
Boehrer, Simone
Beyne-Rauzy, Odile
Prebet, Thomas
Park, Sophie
Guerci, Agnes
Stamatoulas, Aspasia
Chaury, M. P.
Jernival, Tony
Sanhes, Laurence
Tertian, Gerard
Cheze, Stephane
Lim, Eng-Mong
Choufi, Bachra
Caillot, Denis
Wattel, E.
Delaunay, Jacques
Legros, Laurence
Chermat, Fatiha
Isnard, Francoise
Cambier, N.
Slama, Borhane
Roy, Lydia
Damaj, Gandhi
Raffoux, Emmanuel
Dreyfus, Francois
Recher, Christian
Vey, Norbert
Chevret, Sylvie
Fenaux, Pierre
Gardin, Claude
[J]. BLOOD, 2010, 116 (21) : 784 - 784
[3] Cheson BD, 2000, BLOOD, V96, P3671
[4] Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Cheson, Bruce D.
Greenberg, Peter L.
Bennett, John M.
Lowenberg, Bob
Wijermans, Pierre W.
Nimer, Stephen D.
Pinto, Antonio
Beran, Miloslav
de Witte, Theo M.
Stone, Richard M.
Mittelman, Moshe
Sanz, Guillermo F.
Gore, Steven D.
Schiffer, Charles A.
Kantarjian, Hagop
[J]. BLOOD, 2006, 108 (02) : 419 - 425
[5] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Fenaux, Pierre
Mufti, Ghulam J.
Hellstrom-Lindberg, Eva
Santini, Valeria
Finelli, Carlo
Giagounidis, Aristoteles
Schoch, Robert
Gattermann, Norbert
Sanz, Guillermo
List, Alan
Gore, Steven D.
Seymour, John F.
Bennett, John M.
Byrd, John
Backstrom, Jay
Zimmerman, Linda
McKenzie, David
Beach, C. L.
Silverman, Lewis R.
[J]. LANCET ONCOLOGY, 2009, 10 (03) : 223 - 232
[6] A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life
Hellström-Lindberg, E
Gulbrandsen, N
Lindberg, G
Ahlgren, T
Dahl, IMS
Dybedal, I
Grimfors, G
Hesse-Sundin, E
Hjorth, M
Kanter-Lewensohn, L
Linder, O
Luthman, M
Löfvenberg, E
Öberg, G
Porwit-MacDonald, A
Rådlund, A
Samuelsson, J
Tangen, JM
Winquist, I
Wisloff, F
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (06) : 1037 - 1046
[7] Supportive care, growth factors, and new therapies in myelodysplastic syndromes
Hellstrom-Lindberg, Eva
Malcovati, Luca
[J]. BLOOD REVIEWS, 2008, 22 (02) : 75 - 91
[8] Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Itzykson, Raphael
Thepot, Sylvain
Quesnel, Bruno
Dreyfus, Francois
Beyne-Rauzy, Odile
Turlure, Pascal
Vey, Norbert
Recher, Christian
Dartigeas, Caroline
Legros, Laurence
Delaunay, Jacques
Salanoubat, Celia
Visanica, Sorin
Stamatoullas, Aspasia
Isnard, Francoise
Marfaing-Koka, Anne
de Botton, Stephane
Chelghoum, Youcef
Taksin, Anne-Laure
Plantier, Isabelle
Ame, Shanti
Boehrer, Simone
Gardin, Claude
Beach, C. L.
Ades, Lionel
Fenaux, Pierre
[J]. BLOOD, 2011, 117 (02) : 403 - 411
[9] Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
Jädersten, M
Montgomery, SM
Dybedal, I
Porwit-MacDonald, A
Hellström-Lindberg, E
[J]. BLOOD, 2005, 106 (03) : 803 - 811
[10] Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
Jadersten, Martin
Malcovati, Luca
Dybedal, Ingunn
Della Porta, Matteo Giovanni
Invernizzi, Rosangela
Montgomery, Scott M.
Pascutto, Cristiana
Porwit, Anna
Cazzola, Mario
Hellstrom-Lindberg, Eva
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3607 - 3613

← 1 2 →